{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093945","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.006138+00:00","generated_at":"2026-05-31T10:46:28.749888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kura Oncology Q2 net loss $50.8M; cash $491.5M; ziftomenib pivotal data expected early 2025","bullets":["Net loss $50.8M in Q2 2024 vs $37.2M in Q2 2023; R&D expenses $39.7M vs $28.2M.","Cash, equivalents & short-term investments $491.5M at June 30, 2024; runway into 2027.","Ziftomenib completed enrollment of 85 patients in KOMET-001 pivotal trial; FDA Breakthrough Therapy Designation; topline data early 2025.","Phase 1b expansion of KOMET-007 (ziftomenib + ven/aza and 7+3) now enrolling; data expected Q4 2024.","IND cleared for ziftomenib in GIST; proof-of-concept study with imatinib planned H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093945","json":"https://secwatch.observer/filing/0000950170-24-093945.json","markdown":"https://secwatch.observer/filing/0000950170-24-093945.md","text":"https://secwatch.observer/filing/0000950170-24-093945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024093945/0000950170-24-093945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024093945/kura-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:46:28.749888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}